Dec 15, 2022 12:20 JST
Source: Eisai
|
|
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
TOKYO, Dec 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).
Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations have been collaborating in AD research. The Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody E2814 for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab (generic name, development code: BAN2401) was selected as the background anti-amyloid agent.
The collaboration strategically combines Washington University scientists" expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai's extensive experience in drug discovery and development. Using human biology, the aim is to create multiple novel therapeutic candidates as well as discover and identify biomarkers within the next five years. Eisai will have the option rights to develop and commercialize any compounds and biomarkers that meet certain criteria in terms of research and development milestones. In the case that Eisai chooses to exercise the options, Eisai will pay Washington University milestone payments and royalties on future sales of each licensed compounds.
Dr. Teiji Kimura, Ph.D., Academia and Industry Alliance Officer, Deep Human Biology Learning (DHBL) Office of Eisai, commented, "Patients living with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, struggle with critical unmet medical needs, which is the reason neurology is a key therapeutic area for Eisai. By collaborating with world-leading research institutions such as Washington University in St. Louis, Eisai is working to fulfill our human health care mission and provide potential new and targeted disease-modifying therapies with the ultimate goal of achieving a world free of neurodegenerative disease."
About Washington University School of Medicine
WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,700 faculty. Its National Institutes of Health (NIH) research funding portfolio is the fourth largest among U.S. medical schools, has grown 54% in the last five years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,790 faculty physicians practicing at over 60 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children's hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 Eisai Inc (U.S.) Libby Holman 201-753-1945 Libby_Holman@eisai.com
Source: Eisai Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
 Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security May 13, 2025 11:00 JST
|  TOYOTA GAZOO Racing fights back for double points finish May 12, 2025 15:45 JST
|  JCB and Arab Bank launch JCB merchant acquiring operations across Jordan May 12, 2025 11:00 JST
|  Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance May 09, 2025 18:57 JST
|  Valuufy Selected by Global Tech Leader for Environmental Impact Assessment May 09, 2025 18:00 JST
|  Mazda Adopts North American Charging Standard for BEVs launched in Japan May 09, 2025 16:03 JST
|  Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026 May 08, 2025 11:25 JST
|  Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV May 08, 2025 11:08 JST
|  Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China May 07, 2025 19:06 JST
|  Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition May 03, 2025 03:00 JST
|  TOYOTA GAZOO Racing Set for Spa spectacle May 02, 2025 19:29 JST
|  FWD Group reports exceptionally strong first quarter new business update May 02, 2025 17:00 JST
|  Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand May 01, 2025 17:48 JST
|  Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users Apr 30, 2025 17:20 JST
|  Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star Apr 30, 2025 14:17 JST
|  Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki Apr 29, 2025 17:24 JST
|  NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally Apr 28, 2025 16:03 JST
| NEC achieves Japan's longest terrestrial wireless optical communication over 10 km Apr 25, 2025 17:50 JST
|  Olympus Appoints New CEO Apr 25, 2025 15:30 JST
|  DENSO Announces Year-End Financial Results Apr 25, 2025 12:17 JST
|
More Latest Release >>
|